A short-course of Soliris (eculizumab) treatment during relapses may help people with neuromyelitis optica spectrum disorder (NMOSD) recover faster when standard therapies fail, a small study in China suggests. Patients who saw little or no improvement after corticosteroids, with or without plasma exchange, experienced meaningful gains in mobility…
Soliris (eculizumab)
Soliris (eculizumab) is linked to a reduced relapse rate and stabilization of disability progression in people with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-AQP4 antibodies, according to a real-world study in Turkey. “These results support [Soliris] as a valuable therapy for [AQP4-related] NMOSD, while stressing the…
Switching from Soliris (eculizumab) to Enspryng (satralizumab) is a safe and effective approach for neuromyelitis optica spectrum disorder (NMOSD) patients testing positive for antibodies against the AQP4 protein. That’s according to data from five patients in the U.S. who switched treatments due to either preference for route…
Soliris (eculizumab) may help relieve symptoms during severe attacks in the acute phase of neuromyelitis optica spectrum disorder (NMOSD) when other treatments are ineffective, according to a case series study from Japan. The study included five patients who had experienced severe NMOSD attacks that did not respond well…
Note: This column describes the author’s own experiences with Solu-Medrol (methylprednisolone) and the Homepump Eclipse. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Initially, I took a blasé approach to my most recent neuromyelitis optica spectrum disorder…
Nearly all neuroimmunologists treating patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-AQP4 antibodies have prescribed one of the three currently approved therapies: Soliris (eculizumab), Uplizna (inebilizumab-cdon), and Enspryng (satralizumab-mwge). These are the findings of a U.S. survey that also found most responding…
Soliris (eculizumab) has been approved in China to treat adults with neuromyelitis optica spectrum disorder, known as NMO or NMOSD, who test positive for antibodies against the aquaporin-4 (AQP4) protein. The therapy — which works to reduce the risk of relapse and ease inflammation among patients — was approved…
AstraZeneca has announced filing a legal challenge to certain aspects of the U.S. Inflation Reduction Act (IRA), arguing that there may be unintended but harmful consequences for people living with rare diseases such as neuromyelitis optica spectrum disorder (NMOSD). It joins a number of other pharmaceutical companies…
Long-term use of the approved therapy Soliris (eculizumab) safely and effectively prevents relapses in the real world in people with neuromyelitis optica spectrum disorder (NMOSD) and antibodies against the AQP4 protein. That’s according to two-year interim data from an observational study in Japan, where Soliris was approved in…
An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) given the therapy in the PREVENT Phase 3 clinical trial. At its approved dose, Soliris led to rapid, sustained, and complete suppression…
Recent Posts
- 2 approved treatments for NMOSD may work better than off-label one
- It’s important to realize when the caregiver needs care
- MRI scan of waste system in brain may track NMOSD severity, progression
- My mom’s example of strength still guides me in life with NMOSD
- Short course of approved drug effective for treatment-resistant NMOSD